{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:47Z","timestamp":1792513127866,"version":"4.5.0"},"reference-count":215,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T00:00:00Z","timestamp":1701561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Powell Gene Therapy Center","award":["U01-NS116752-01A1(MC)"],"award-info":[{"award-number":["U01-NS116752-01A1(MC)"]}]},{"name":"Powell Gene Therapy Center","award":["R01 HL139708-02 (BJB)"],"award-info":[{"award-number":["R01 HL139708-02 (BJB)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Efficient and targeted delivery of a DNA payload is vital for developing safe gene therapy. Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlight. Adenovirus vectors can be used in gene therapy by altering the wild-type virus and making it replication-defective; specific viral genes can be removed and replaced with a segment that holds a therapeutic gene, and this vector can be used as delivery vehicle for tissue specific gene delivery. Modified conditionally replicative\u2013oncolytic adenoviruses target tumors exclusively and have been studied in clinical trials extensively. This comprehensive review seeks to offer a summary of adenovirus vectors, exploring their characteristics, genetic enhancements, and diverse applications in clinical and preclinical settings. A significant emphasis is placed on their crucial role in advancing cancer therapy and the latest breakthroughs in vaccine clinical trials for various diseases. Additionally, we tackle current challenges and future avenues for optimizing adenovirus vectors, promising to open new frontiers in the fields of cell and gene therapies.<\/jats:p>","DOI":"10.3390\/v15122378","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T03:40:58Z","timestamp":1701661258000},"page":"2378","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Evolving Horizons: Adenovirus Vectors\u2019 Timeless Influence on Cancer, Gene Therapy and Vaccines"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-5354","authenticated-orcid":false,"given":"Prasad D.","family":"Trivedi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,3]]},"reference":[{"key":"ref_1","unstructured":"FDA (2023). Approved Cellular and Gene Therapy Products, FDA."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S., Kakoti, B.B., Kaushik, A., and Jesawadawala, M. (2023). Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 11.","DOI":"10.3390\/vaccines11020432"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/or.2021.8000","article-title":"Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review)","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.molmed.2022.10.001","article-title":"Adenoviruses in medicine: Innocuous pathogen, predator, or partner","volume":"29","author":"MacNeil","year":"2023","journal-title":"Trends Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1126\/science.288.5468.951","article-title":"Gene therapy on trial","volume":"288","author":"Marshall","year":"2000","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene Therapy Death Prompts Review of Adenovirus Vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.biomaterials.2013.09.096","article-title":"The effect of adenovirus-conjugated NDRG2 on p53-mediated apoptosis of hepatocarcinoma cells through attenuation of nucleotide excision repair capacity","volume":"35","author":"Cao","year":"2014","journal-title":"Biomaterials"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: Construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"BioTechniques"},{"key":"ref_11","first-page":"616","article-title":"Development of adenovirus vectors for the expression of heterologous genes","volume":"6","author":"Berkner","year":"1998","journal-title":"Biotechniques"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gallardo, J., P\u00e9rez-Illana, M., Mart\u00edn-Gonz\u00e1lez, N., and San Mart\u00edn, C. (2021). Adenovirus Structure: What Is New?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105240"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0022-2836(79)90294-8","article-title":"The nucleotide sequences at the termini of adenovirus-2 DNA","volume":"128","author":"Arrand","year":"1979","journal-title":"J. Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.1194922","article-title":"Looking Inside Adenovirus","volume":"329","author":"Harrison","year":"2010","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ahi, Y.S., and Mittal, S.K. (2016). Components of adenovirus genome packaging. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.01503"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Jennings, M.R., and Parks, R.J. (2023). Human Adenovirus Gene Expression and Replication Is Regulated through Dynamic Changes in Nucleoprotein Structure throughout Infection. Viruses, 15.","DOI":"10.3390\/v15010161"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses: Update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Baker, A.T., Aguirre-Hern\u00e1ndez, C., Halld\u00e9n, G., and Parker, A.L. (2018). Designer oncolytic adenovirus: Coming of age. Cancers, 10.","DOI":"10.20944\/preprints201805.0273.v2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sallard, E., Zhang, W., Aydin, M., Schr\u00f6er, K., and Ehrhardt, A. (2023). The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine. Viruses, 15.","DOI":"10.3390\/v15010204"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41598-018-37249-4","article-title":"Molecular Evolution of Human Adenovirus (HAdV) Species C","volume":"9","author":"Dhingra","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1002\/jgm.496","article-title":"Adenoviral vectors for gene transfer and therapy","volume":"6","author":"Volpers","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus entry: From infection to immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/JVI.72.5.4049-4056.1998","article-title":"Control of adenovirus early gene expression during the late phase of infection","volume":"72","author":"Fessler","year":"1998","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1128\/JVI.78.4.1782-1791.2004","article-title":"Activation of the early-late switch in adenovirus type 5 major late transcription unit expression by L4 gene products","volume":"78","author":"Farley","year":"2004","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2019.01182","article-title":"Oncolytic Adenovirus\u2014A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC","volume":"9","author":"Abudoureyimu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virusres.2009.10.008","article-title":"Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor beta1-induced apoptosis","volume":"147","author":"Tarakanova","year":"2010","journal-title":"Virus Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.cgt.7701054","article-title":"Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy","volume":"14","author":"Yang","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Watanabe, M., Nishikawaji, Y., Kawakami, H., and Kosai, K.-I. (2021). Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy. Viruses, 13.","DOI":"10.3390\/v13122502"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1128\/JVI.78.13.7227-7247.2004","article-title":"Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells","volume":"78","author":"Gaden","year":"2004","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21873\/anticanres.16190","article-title":"Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35","volume":"43","author":"Ono","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dai, H., Xi, H., Huang, L., Yuan, Z., Liao, Y., Tang, Y., Liao, J., Min, L., and Yu, Z. (2020). Molecular Epidemiology and Clinical Features Analysis of Respiratory Adenovirus Infections Reveals Correlations between Genotype, Inflammatory Biomarkers, and Disease Severity. Biomed. Res. Int., 2020.","DOI":"10.1155\/2020\/4357910"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5501\/wjv.v12.i3.136","article-title":"Gastrointestinal tract and viral pathogens","volume":"12","author":"Jagirdhar","year":"2023","journal-title":"World J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Muto, T., Imaizumi, S., and Kamoi, K. (2023). Viral Conjunctivitis. Viruses, 15.","DOI":"10.3390\/v15030676"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bj.2021.08.009","article-title":"Human adenovirus infections in pediatric population\u2014An update on clinico-pathologic correlation","volume":"45","author":"Shieh","year":"2022","journal-title":"Biomed. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2018.09.036","article-title":"Adenovirus-Associated Central Nervous System Disease in Children","volume":"205","author":"Schwartz","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coviro.2021.11.006","article-title":"Seeing and touching adenovirus: Complementary approaches for understanding assembly and disassembly of a complex virion","volume":"52","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature18317","article-title":"A core viral protein binds host nucleosomes to sequester immune danger signals","volume":"535","author":"Avgousti","year":"2016","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e114162","DOI":"10.15252\/embj.2023114162","article-title":"Changes in adenoviral chromatin organization precede early gene activation upon infection","volume":"42","author":"Schwartz","year":"2023","journal-title":"EMBO J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Keiser, M.S., and Davidson, B.L. (2018). Viral Vectors for Gene Transfer. Curr. Protoc. Mouse Biol., 8.","DOI":"10.1002\/cpmo.58"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hoeben, R.C., and Uil, T.G. (2013). Adenovirus DNA replication. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a013003"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1128\/JVI.73.7.6048-6055.1999","article-title":"Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3","volume":"73","author":"Gorziglia","year":"1999","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10616-006-0008-2","article-title":"Development of a Serum-free Suspension Process for the Production of a Conditionally Replicating Adenovirus using A549 Cells","volume":"49","author":"Longley","year":"2005","journal-title":"Cytotechnology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1535-6108(02)00060-0","article-title":"Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents","volume":"1","author":"Johnson","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5483\/BMBRep.2020.53.11.185","article-title":"Helper virus-free gutless adenovirus (HF-GLAd): A new platform for gene therapy","volume":"53","author":"Liu","year":"2020","journal-title":"BMB Rep."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ricobaraza, A., Gonzalez-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., and Hernandez-Alcoceba, R. (2020). High-capacity adenoviral vectors: Expanding the scope of gene therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103643"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","article-title":"Production of first generation adenovirus vectors: A review","volume":"7","author":"Danthinne","year":"2000","journal-title":"Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1006\/mthe.2000.0167","article-title":"DNA Virus Vectors II","volume":"1","author":"Duan","year":"2000","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12985-016-0576-5","article-title":"Cloning and rescue of the genome of Bombyx mori bidensovirus, and characterization of a recombinant virus","volume":"13","author":"Zhang","year":"2016","journal-title":"Virol. J."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rosewell, A., Vetrini, F., and Ng, P. (2011). Helper-Dependent Adenoviral Vectors. J. Genet. Syndr. Gene Ther.","DOI":"10.4172\/2157-7412.S5-001"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"17771","DOI":"10.1038\/s41598-017-17651-0","article-title":"Site-specific chromosomal gene insertion: Flp recombinase versus Cas9 nuclease","volume":"7","author":"Phan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Guo, X., Sun, Y., Chen, J., Zou, X., Hou, W., Tan, W., Hung, T., and Lu, Z. (2022). Restriction-Assembly: A Solution to Construct Novel Adenovirus Vector. Viruses, 14.","DOI":"10.3390\/v14030546"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Anselmo, A.C., and Mitragotri, S. (2022). Viral vector-based gene therapies in the clinic. Bioeng. Transl. Med., 7.","DOI":"10.1002\/btm2.10258"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.2017680","article-title":"Adenovirus-mediated transfer of a recombinant \u03b11-antitrypsin gene to the lung epithelium in vivo","volume":"252","author":"Rosenfeld","year":"1991","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.biotechadv.2008.10.003","article-title":"From the first to the third generation adenoviral vector: What parameters are governing the production yield?","volume":"27","author":"Dormond","year":"2009","journal-title":"Biotechnol. Adv."},{"key":"ref_60","unstructured":"Rininger, J., Fennell, A., Schoukroun-Barnes, L., Peterson, C., and Speidel, J. (2019). Bioprocess International, Latham Biopharm Group."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2022.228","article-title":"Review of Safety Data for Adenovirus 5 as a Delivery Vector for Intratumoral Cancer Gene Therapy","volume":"34","author":"Sheldon","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","article-title":"The oncolytic virus in cancer diagnosis and treatment","volume":"10","author":"Cao","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2017.03.002","article-title":"Combining oncolytic virotherapy with p53 tumor suppressor gene therapy","volume":"5","author":"Bressy","year":"2017","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.cgt.7700851","article-title":"Combined HSV-TK\/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: Biological and clinical results","volume":"12","author":"Colombo","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ymthe.2005.11.022","article-title":"Biological response determinants in HSV-tk+ ganciclovir gene therapy for prostate cancer","volume":"13","author":"Ayala","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1089\/hum.2007.074","article-title":"Long-term outcome of phase I\/II clinical trial of Ad-OC-TK\/VAL gene therapy for hormone-refractory metastatic prostate cancer","volume":"18","author":"Shirakawa","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/gt.2013.40","article-title":"Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer","volume":"20","author":"Freytag","year":"2013","journal-title":"Gene Ther."},{"key":"ref_70","first-page":"45","article-title":"Advances in the techniques and methodologies of cancer gene therapy","volume":"27","author":"Sun","year":"2019","journal-title":"Discov. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.drudis.2015.07.006","article-title":"Reactivating mutant p53 using small molecules as zinc metallochaperones: Awakening a sleeping giant in cancer","volume":"20","author":"Blanden","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00262-012-1242-4","article-title":"Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: Results from a phase II trial","volume":"61","author":"Ellebaek","year":"2012","journal-title":"Cancer Immunol. Immunother"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.3892\/mmr.2015.3227","article-title":"Role of adenovirus-mediated retinoblastoma 94 in the treatment of human non-small cell lung cancer","volume":"11","author":"Liu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/cgt.2015.59","article-title":"Synergistic tumor suppression by adenovirus-mediated ING4\/PTEN double gene therapy for gastric cancer","volume":"23","author":"Zhang","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0042-6822(87)90441-7","article-title":"Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection","volume":"156","author":"Barker","year":"1987","journal-title":"Virology"},{"key":"ref_78","first-page":"6359","article-title":"Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/OV.S100072","article-title":"Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma","volume":"6","author":"Babiker","year":"2017","journal-title":"Oncolytic Virother."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2023). Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. Viruses, 15.","DOI":"10.3390\/v15030698"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Liu, Z., Li, L., Wu, J., Zhang, H., Zhang, H., Lei, T., and Xu, B. (2021). Oncolytic adenovirus: Prospects for cancer immunotherapy. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.707290"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhang, C., Miao, J., Wang, Z., Wang, Z., Cheng, Z., Wang, P., Dunmall, L.S.C., Lemoine, N.R., and Wang, Y. (2020). A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma. Cells, 9.","DOI":"10.3390\/cells9112438"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.2217\/fon-2022-0481","article-title":"BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors","volume":"18","author":"Kesari","year":"2022","journal-title":"Future Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2106\/00004623-199907000-00002","article-title":"The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats","volume":"81","author":"Lieberman","year":"1999","journal-title":"JBJS"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.gt.3301960","article-title":"Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: A comparison of adenoviral vectors and liposomes","volume":"10","author":"Park","year":"2003","journal-title":"Gene Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.gt.3302298","article-title":"Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery","volume":"11","author":"Kang","year":"2004","journal-title":"Gene Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.BRS.0000058946.64222.92","article-title":"Potential use of Sox9 gene therapy for intervertebral degenerative disc disease","volume":"28","author":"Paul","year":"2003","journal-title":"Spine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jhsa.2004.08.010","article-title":"Characterization of adenovirus-mediated gene transfer in rabbit flexor tendons","volume":"30","author":"Mehta","year":"2005","journal-title":"J. Hand Surg."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2106\/00004623-200706000-00021","article-title":"BMP-14 gene therapy increases tendon tensile strength in a rat model of Achilles tendon injury","volume":"89","author":"Bolt","year":"2007","journal-title":"JBJS"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/neurintsurg-2021-018190","article-title":"Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors","volume":"14","author":"Chen","year":"2022","journal-title":"J. Neurointerv. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/bloodadvances.2022007975","article-title":"In vivo HSC transduction in rhesus macaques with an HDAd5\/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4","volume":"6","author":"Wang","year":"2022","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jmoldx.2023.03.004","article-title":"Droplet Digital PCR Development for Adenovirus Load Monitoring in Children after Hematopoietic Stem Cell Transplantation","volume":"25","author":"Haruta","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/infdis\/140.1.48","article-title":"Simultaneous administration of live, enteric-coated adenovirus types 4, 7, and 21 vaccines: Safety and immunogenicity","volume":"140","author":"Takafuji","year":"1979","journal-title":"J. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: A randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: A combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26. ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e055596","DOI":"10.1136\/bmjopen-2021-055596","article-title":"Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo","volume":"12","author":"Grais","year":"2022","journal-title":"BMJ Open"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14712598.2018.1404572","article-title":"From bench to almost bedside: The long road to a licensed Ebola virus vaccine","volume":"18","author":"Wong","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(18)31710-0","article-title":"Prevention of Ebola virus disease through vaccination: Where we are in 2018","volume":"392","author":"Lane","year":"2018","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","article-title":"Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: A phase 1, open-label, dose-escalation clinical trial","volume":"23","author":"Mwesigwa","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26. ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Wan, M., Yang, X., Sun, J., Ding, X., Chen, Z., Su, W., Cai, L., Hou, A., Sun, B., and Gao, F. (2023). An Adenovirus-Based Recombinant Herpes Simplex Virus 2 (HSV-2) Therapeutic Vaccine Is Highly Protective against Acute and Recurrent HSV-2 Disease in a Guinea Pig Model. Viruses, 15.","DOI":"10.3390\/v15010219"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1084\/jem.20072681","article-title":"The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?","volume":"205","author":"Sekaly","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Churchyard, G.J., Morgan, C., Adams, E., Hural, J., Graham, B.S., Moodie, Z., Grove, D., Gray, G., Bekker, L.-G., and McElrath, M.J. (2011). A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021225"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiu485","article-title":"Induction of HIV-1\u2013specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans","volume":"211","author":"Baden","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1000461","DOI":"10.4172\/2155-6113.1000461","article-title":"Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals","volume":"6","author":"Fuchs","year":"2015","journal-title":"J. AIDS Clin. Res."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Check Hayden, E. (2009). Mystery of HIV vaccine failure deepens. Nature.","DOI":"10.1038\/news.2009.707"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/ijc.31166","article-title":"Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins","volume":"142","author":"Cuburu","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12985-021-01516-0","article-title":"Performance of BioFire array or QuickVue influenza A + B test versus a validation qPCR assay for detection of influenza A during a volunteer A\/California\/2009\/H1N1 challenge study","volume":"18","author":"McIlwain","year":"2021","journal-title":"Virol. J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: A placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Choi, G., Rejinold, N.S., Piao, H., Ryu, Y.B., Kwon, H.J., Lee, I.C., Seo, J.I., Yoo, H.H., Jin, G.W., and Choy, J.H. (2023). The Next Generation COVID-19 Antiviral; Niclosamide-Based Inorganic Nanohybrid System Kills SARS-CoV-2. Small, e2305148.","DOI":"10.1002\/smll.202305148"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","article-title":"Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): An open-label, non-randomised, dose-escalation, phase 1b trial","volume":"3","author":"Bosaeed","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_120","unstructured":"Kimberlin, D.W. (2006). Red Book: 2006 Report of Committee on Infectious Diseases, American Academy of Pediatrics."},{"key":"ref_121","unstructured":"WHO (2019). Guidelines on the Quality, Safety and Efficacy of Respiratory Syncytial Virus Vaccines."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and Safety of an Ad26.RSV.preF\u2013RSV preF Protein Vaccine in Older Adults","volume":"388","author":"Falsey","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/infdis\/jiac407","article-title":"Phase 1\/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18\u201350 Years and RSV-Seropositive Children 12\u201324 Months","volume":"227","author":"Stuart","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/infdis\/jiaa409","article-title":"Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered with an Influenza Vaccine in Older Adults","volume":"223","author":"Sadoff","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_125","unstructured":"GSK (2023). US FDA Approves GSK\u2019s Arexvy, the World\u2019s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults, GSK."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_127","unstructured":"FDA (2023). FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants, FDA."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Hao, M., Bian, T., Fu, G., Chen, Y., Fang, T., Zhao, C., Liu, S., Yu, C., Li, J., and Chen, W. (2023). An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1114226"},{"key":"ref_129","unstructured":"WHO (2023). WHO Coronavirus (COVID-19) Dashboard."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"ofac418","DOI":"10.1093\/ofid\/ofac418","article-title":"Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine with the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study","volume":"9","author":"Clemens","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1093\/cid\/ciac439","article-title":"Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States","volume":"75","author":"Lewis","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1200353","DOI":"10.3389\/fpubh.2023.1200353","article-title":"COVID-19 and herpes zoster: A call to action","volume":"11","author":"Noushad","year":"2023","journal-title":"Front. Public Health"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2175558","DOI":"10.1080\/21645515.2023.2175558","article-title":"Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster","volume":"19","author":"Ulaszewska","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(16)00080-5","article-title":"Anticipating the international spread of Zika virus from Brazil","volume":"387","author":"Bogoch","year":"2016","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.01722-17","article-title":"Recombinant chimpanzee adenovirus vaccine AdC7-M\/E protects against Zika virus infection and testis damage","volume":"92","author":"Xu","year":"2018","journal-title":"J. Virol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/infdis\/jiy187","article-title":"Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of Zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models","volume":"218","author":"Guo","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26. ZIKV. 001, an Ad26-vectored anti\u2013Zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100432","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.vaccine.2023.02.055","article-title":"Generation of a thermostable, oral Zika vaccine that protects against virus challenge in non-human primates","volume":"41","author":"Bacon","year":"2023","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"eade3901","DOI":"10.1126\/scitranslmed.ade3901","article-title":"An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease","volume":"15","author":"Dold","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"895020","DOI":"10.3389\/fimmu.2022.895020","article-title":"Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.00004-07","article-title":"Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon","volume":"75","author":"Wieland","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.4049\/jimmunol.1400676","article-title":"Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge","volume":"193","author":"Darrah","year":"2014","journal-title":"J. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e00014-18","DOI":"10.1128\/IAI.00014-18","article-title":"Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine","volume":"86","author":"Stylianou","year":"2018","journal-title":"Infect. Immun."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/mi.2015.29","article-title":"Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: Overcoming local anti-human adenovirus immunity for potent TB protection","volume":"8","author":"Jeyanathan","year":"2015","journal-title":"Mucosal Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/infdis\/jiz306","article-title":"Single-dose mucosal immunotherapy with chimpanzee adenovirus-based vaccine accelerates tuberculosis disease control and limits its rebound after antibiotic cessation","volume":"220","author":"Afkhami","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Sheehan, S., Harris, S.A., Satti, I., Hokey, D.A., Dheenadhayalan, V., Stockdale, L., Thomas, Z.-R.M., Minhinnick, A., Wilkie, M., and Vermaak, S. (2015). A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141687"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime\u2013MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"key":"ref_151","unstructured":"Buck, E., and Finnigan, N.A. (2023). StatPearls, StatPearls Publishing LLC.. StatPearls Publishing Copyright \u00a9 2023."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/IAI.74.1.313-320.2006","article-title":"Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice","volume":"74","author":"Ophorst","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0264-410X(98)00181-9","article-title":"Efficient induction of protective anti-malaria immunity by recombinant adenovirus","volume":"16","author":"Rodrigues","year":"1998","journal-title":"Vaccine"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Sedegah, M., Peters, B., Hollingdale, M.R., Ganeshan, H.D., Huang, J., Farooq, F., Belmonte, M.N., Belmonte, A.D., Limbach, K.J., and Diggs, C. (2016). Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168952"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/21645515.2015.1019186","article-title":"Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming","volume":"11","author":"Sedegah","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Sedegah, M., Hollingdale, M.R., Farooq, F., Ganeshan, H., Belmonte, M., Kim, Y., Peters, B., Sette, A., Huang, J., and McGrath, S. (2014). Sterile immunity to malaria after DNA prime\/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106241"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4161\/hv.24941","article-title":"Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection","volume":"9","author":"Tamminga","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","article-title":"Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: Safety, immunogenicity and protective efficacy of the CSP component","volume":"6","author":"Tamminga","year":"2011","journal-title":"PLoS ONE"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: Safety and immunogenicity in seronegative adults","volume":"6","author":"Sedegah","year":"2011","journal-title":"PLoS ONE"},{"key":"ref_160","unstructured":"WHO (2023). WHO Recommends R21\/Matrix-M Vaccine for Malaria Prevention in Updated Advice on Immunization."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Alvar, J., V\u00e9lez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., Boer, M.D., and WHO Leishmaniasis Control Team (2012). Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035671"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan","volume":"29","author":"Younis","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector","volume":"205","author":"Duncan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"234ra56","DOI":"10.1126\/scitranslmed.3008222","article-title":"Modular multiantigen T cell epitope\u2013enriched DNA vaccine against human leishmaniasis","volume":"6","author":"Das","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nm933","article-title":"Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses","volume":"9","author":"Alexander","year":"2003","journal-title":"Nat. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2007.05.010","article-title":"Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis","volume":"25","author":"Moreno","year":"2007","journal-title":"Vaccine"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Osman, M., Mistry, A., Keding, A., Gabe, R., Cook, E., Forrester, S., Wiggins, R., Di Marco, S., Colloca, S., and Siani, L. (2017). A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. PLoS Neglected Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005527"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"200","DOI":"10.12688\/wellcomeopenres.17951.1","article-title":"LEISH2b\u2014A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis","volume":"7","author":"Lacey","year":"2022","journal-title":"Wellcome Open Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jso.27318","article-title":"Contemporary surgical management of colorectal cancer in Lynch syndrome","volume":"127","author":"Abbass","year":"2023","journal-title":"J. Surg. Oncol."},{"key":"ref_170","unstructured":"Richards, J.R., and Le, J.K. (2023). StatPearls, StatPearls Publishing LLC.. StatPearls Publishing Copyright \u00a9 2023."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1021\/acs.jmedchem.3c00366","article-title":"Anti-cocaine Vaccine Development: Where Are We Now and Where Are We Going?","volume":"66","author":"Stephenson","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Havlicek, D.F., Rosenberg, J.B., De, B.P., Hicks, M.J., Sondhi, D., Kaminsky, S.M., and Crystal, R.G. (2020). Cocaine vaccine dAd5GNE protects against moderate daily and high-dose \u201cbinge\u201d cocaine use. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0239780"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acs.bioconjchem.2c00346","article-title":"Modular Adapters Utilizing Binders of Different Molecular Types Expand Cell-Targeting Options for Adenovirus Gene Delivery","volume":"33","author":"Freitag","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: Comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J. Virol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Bots, S.T., and Hoeben, R.C. (2020). Non-human primate-derived adenoviruses for future use as oncolytic agents?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144821"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2013.071","article-title":"Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors","volume":"24","author":"Ng","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Gonzalez-Aparicio, M., Bunuales, M., de Landazuri, I.O., Prieto, J., and Hernandez--Alcoceba, R. (2023). Application of a split-Cre system for high-capacity adenoviral vector amplification. Biotechnol. J., 18.","DOI":"10.1002\/biot.202200227"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1156714","DOI":"10.3389\/fimmu.2023.1156714","article-title":"Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer","volume":"14","author":"Nocchi","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"eadd4853","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.gt.3301190","article-title":"An improved anion-exchange HPLC method for the detection and purification of adenoviral particles","volume":"7","author":"Blanche","year":"2000","journal-title":"Gene Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1089\/hum.1995.6.11-1403","article-title":"Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography","volume":"6","author":"Huyghe","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1089\/10430340260355338","article-title":"A new scalable method for the purification of recombinant adenovirus vectors","volume":"13","author":"Green","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"25","DOI":"10.12665\/J11.Hutchins","article-title":"Development of a Reference Material for Characterizing Adenovirus Vectors BETH HUTCHINS","volume":"1","author":"Hutchins","year":"2002","journal-title":"BioProcess J."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/fpd.2023.0011","article-title":"Establishment of Digital PCR Method and Reference Material for Adenoviruses 40 and 41","volume":"20","author":"Chen","year":"2023","journal-title":"Foodborne Pathog. Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5455\/OVJ.2023.v13.i2.4","article-title":"TaqMan probe-based qPCR method for specific detection and quantification of fowl adenovirus 8b challenge from chickens inoculated with live attenuated or inactivated virus","volume":"13","author":"Ugwu","year":"2023","journal-title":"Open Vet. J."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Abdullah, O., Fall, A., Forman, M., Howard, C., Klein, E., and Mostafa, H.H. (2023). Respiratory Adenovirus Quantification with a Droplet Digital Polymerase Chain Reaction (ddPCR) Assay. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.00269-23"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Santander-Parra, S.H., Caza, M., and Nu\u00f1ez, L. (2023). Detection, Quantification and Molecular Characterization of Fowl Adenoviruses Circulating in Ecuadorian Chicken Flocks during 2019\u20132021. Vet. Sci., 10.","DOI":"10.3390\/vetsci10020115"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Li, R., Zhao, Y., Fan, H., Chen, M., Hu, W., Zhang, Q., Jin, M., Liu, G.L., and Huang, L. (2022). Versatile nanorobot hand biosensor for specific capture and ultrasensitive quantification of viral nanoparticles. Mater. Today Bio, 16.","DOI":"10.1016\/j.mtbio.2022.100444"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"36825","DOI":"10.1021\/acsomega.2c05325","article-title":"Proteomic Analysis of Adenovirus 5 by UHPLC-MS\/MS: Development of a Robust and Reproducible Sample Preparation Workflow","volume":"7","author":"Zarei","year":"2022","journal-title":"ACS Omega"},{"key":"ref_193","unstructured":"Mahy, B.W.J., and Van Regenmortel, M.H.V. (2008). Encyclopedia of Virology, Academic Press. [3rd ed.]."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1095343","DOI":"10.3389\/fpubh.2023.1095343","article-title":"A seroepidemiological survey of adenovirus type 7 circulation among healthy adults in China and in Sierra Leone, West Africa","volume":"11","author":"Wang","year":"2023","journal-title":"Front. Public Health"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"100434","DOI":"10.1016\/j.onehlt.2022.100434","article-title":"Simian adenoviruses: Molecular and serological survey in monkeys and humans in Thailand","volume":"15","author":"Kosoltanapiwat","year":"2022","journal-title":"One Health"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e16986","DOI":"10.1016\/j.heliyon.2023.e16986","article-title":"Seroprevalence of neutralizing antibodies to human mastadenovirus serotypes 3 and 7 in healthy children from guangdong province","volume":"9","author":"Kuang","year":"2023","journal-title":"Heliyon"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Klann, P.J., Wang, X., Elfert, A., Zhang, W., K\u00f6hler, C., G\u00fcttsches, A.-K., Jacobsen, F., Weyen, U., Roos, A., and Ehrke-Schulz, E. (2022). Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders. Viruses, 15.","DOI":"10.3390\/v15010079"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Sapu\u0142a, M., Suchacz, M., Koz\u0142owska, J., Cybula, A., Siwak, E., Krankowska, D., and Wierci\u0144ska-Drapa\u0142o, A. (2022). Adenovirus 36 Infection in People Living with HIV-An Epidemiological Study of Seroprevalence and Associations with Cardiovascular Risk Factors. Viruses, 14.","DOI":"10.3390\/v14081639"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.virs.2022.06.006","article-title":"Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China","volume":"37","author":"Yi","year":"2022","journal-title":"Virol. Sin."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"106740","DOI":"10.1016\/j.actatropica.2022.106740","article-title":"Herpesvirus and adenovirus surveillance in threatened wild West Indian (Trichechus manatus) and Amazonian manatees (Trichechus inunguis), Brazil","volume":"237","author":"Ewbank","year":"2023","journal-title":"Acta Trop."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.ymthe.2021.10.020","article-title":"Scratching the surface of RGD-directed AAV capsid engineering","volume":"29","author":"Zolotukhin","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymthe.2006.01.010","article-title":"Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells","volume":"14","author":"Bauerschmitz","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Bates, E.A., Lovatt, C., Plein, A.R., Davies, J.A., Siebzehnrubl, F.A., and Parker, A.L. (2023). Engineering Adenoviral Vectors with Improved GBM Selectivity. Viruses, 15.","DOI":"10.20944\/preprints202304.0027.v1"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1188392","DOI":"10.3389\/fimmu.2023.1188392","article-title":"The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2\/K18-hACE2 mouse infection model","volume":"14","author":"Dickson","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.omtm.2021.12.006","article-title":"Comparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences","volume":"24","author":"Trivedi","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2021.02.015","article-title":"NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific\/timely manner with the HSV platform","volume":"21","author":"Yu","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26. COV2. S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.omto.2021.11.006","article-title":"Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance","volume":"23","author":"Green","year":"2021","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene Firadenovec: First Approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"ref_215","unstructured":"Ferring, P. (2023). First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN\u00ae (Nadofaragene Firadenovec-Vncg), BusinessWire."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2378\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:02Z","timestamp":1760132222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,3]]},"references-count":215,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["v15122378"],"URL":"https:\/\/doi.org\/10.3390\/v15122378","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,3]]}}}